

2024 1Q Results

May 2024



China's Leading Innovative Pharmaceutical Enterprise



R&D Capabilities

- **8** R&D platforms
- **5** R&D centres located in China & the U.S.
- ~ **2,000** R&D professionals
- ~ **300** R&D projects (~**130** innovative projects)



Commercialization Capabilities

- **10,000+** professional sales personnel
- Covered **35,000+** medical institutions across the country, of which **2,900+** Class 3 hospitals (more than 90%), **7,000+** Class 2 hospitals (more than 70%), **26,000+** other terminals and **350,000+** drug stores
- Products exported to **114** countries/regions in 6 continents, including the U.S. and Europe; marketing centers established in the U.S., Germany and Brazil



Manufacturing Capabilities

- **10+** pharmaceutical production bases
- Nano formulation: **27** production lines built with production capacity of **20M** doses/year; **2** production lines under construction with production capacity of **2M** doses/year
- Biologics: fermentation capacity of **40,000L**
- Chemical drugs: production capacity of OSD~**30B** tablets/year, production capacity of injection ~**3B** doses/year
- mRNA vaccines: GMP-compliant production plant has been built
- siRNA: 2 pilot scale production lines has been built; commercial scale production line is under construction





2024 1Q Highlights

R&D

1 new drug approvals:

- Mingfule(AIS): first approved in China in similar products, which is the second indication


18 IND approvals :

China

7 for the first indication
9 for additional indications

North America

2 for the first indication
-JMT106 injection(GPC3/INF)
-SYH2039 tablet (MAT2A inhibitor)



Results

- Revenue increased by **11.5%** to **RMB 8.98 B**
- Underlying profit attributable to shareholders* (see page 6) increased by **11.6%** to **RMB 17.2 B**



01

**Financial
Highlights**

02

**Business
Review**

03

**R&D
Capabilities**

04

Pipeline

05

BD & ESG



Part 01

Financial Highlights

Financial Highlights


Unit: RMB' M

	2024 1Q	2023 1Q	Change
Revenue	8,983	8,053	+11.5%
Gross profit	6,495	5,519	+17.7%
Gross profit margin	72.3%	68.5%	+3.8%
R&D expenses	1,169	1,008	+16.0%
Underlying profit attributable to shareholders*	1,724	1,545	+11.6%
Reported profit attributable to shareholders	1,613	1,429	+12.9%
Basic earnings per share (RMB cents)			
• Based on underlying profit attributable to shareholders	14.55	12.96	+12.3%
• Based on reported profit attributable to shareholders	13.61	11.99	+13.5%


*Note:

Underlying profit attributable to shareholders, a non-HKFRS measure, represents profit excluding fair-value changes on financial assets measured at FVTPL and employee share-based compensation expense.


Revenue



Underlying profit attributable to shareholders



Reported profit attributable to shareholders



Revenue

Revenue by product category

Unit: RMB' M

	2024 1Q	2023 1Q	Change
Finished drugs	7,561	6,422	+17.7%
Bulk vitamin C	486	551	-11.8%
Bulk antibiotics	449	466	-3.6%
Functional Food and Others	486	615	-21.0%



Finished drug revenue

Unit: RMB 'M

	2024 1Q	2023 1Q	Change
Nervous system	2,707	2,125	+27.4%
Oncology	1,611	1,444	+11.6%
Anti-infective	1,350	1,230	+9.8%
Cardiovascular	720	589	+22.3%
Respiratory system	467	498	-6.2%
Digestion & metabolism	314	196	+60.0%
Others	392	304	+28.5%
License fee income	-	34	-

Note: certain percentage changes of financial figures contained in this material are calculated based on the corresponding financial figures in RMB for two periods/years, rounded to the nearest thousand. Therefore, the percentage changes listed in certain tables may differ from those calculated based on the financial figures in RMB for two periods/years, which are presented in million.



Operating Profit

Unit: RMB' M

	2024 1Q	2023 1Q	Change	2024 1Q OPM	2023 1Q OPM	Change
Finished drugs	1,885	1,621	+16.3%	24.9%	25.2%	-0.3%
Bulk vitamin C	13	31	-60.1%	2.6%	5.7%	-3.1%
Bulk antibiotics	106	26	+301.7%	23.6%	5.7%	+17.9%
Functional Food and Others	121	144	-15.7%	24.9%	23.4%	+1.5%


Note: certain percentage changes of financial figures contained in this material are calculated based on the corresponding financial figures in RMB for two periods/years, rounded to the nearest thousand. Therefore, the percentage changes listed in certain tables may differ from those calculated based on the financial figures in RMB for two periods/years, which are presented in million.



Part 02

Business Review

Finished Drugs Overview by Therapeutic Areas



Nervous system	<ul style="list-style-type: none"> Major products include NBP (butylphthalide soft capsules, butylphthalide and sodium chloride injection), Shuanling (pentoxifylline extended-release tablets, pentoxifylline injection), Oulaining (oxiracetam capsules, oxiracetam for injection), Enxi (pramipexole dihydrochloride tablets), Enliwei (lacosamide injection, lacosamide tablets), and Oushuan (paliperidone extended-release tablets)
Oncology	<ul style="list-style-type: none"> Major products include Duomeisu (doxorubicin hydrochloride liposome injection), Jinyouli (PEG-rhG-CSF injection), Keaili (paclitaxel for injection (albuminbound)) Duoenda (mitoxantrone hydrochloride liposome injection), Duoenyi (irinotecan hydrochloride liposome injection), Jinlitai (Narlumobart injection), Copiktra (duvelisib capsules) and Geruite (lenvatinib mesilate capsules)
Anti-infective	<ul style="list-style-type: none"> Major products include Anfulike (amphotericin B cholesteryl sulfate complex for injection), Shuluoke (meropenem for injection), Nuomoling (amoxicillin capsules), Xianqu (Ceftriaxone Sodium for Injection), Xianwu (Cefazolin Sodium for Injection), Zhongnuo Lixin (Cefuroxime Sodium For Injection), and Weihong (azithromycin tablets/capsules/enteric-coated tablets, azithromycin for injection)
Cardio-vascular	<ul style="list-style-type: none"> Major products include Xuanning (levamlodipine maleate tablets and dispersible tablets), Mingfule (recombinant human TNK tissue-type plasminogen activator for injection), Encun (clopidogrel bisulfate tablets), Daxinning (dronedarone hydrochloride tablets), Abikang (Aspirin enteric-coated tablets), Yishuning (nifedipine controlled-release tablets), and Meiluolin (Ticagrelor tablets)
Respiratory system	<ul style="list-style-type: none"> Major products include Yiluoda (nintedanib capsules), Qixin (oseltamivir phosphate capsules), Qixiao (arbidol hydrochloride tablets), Nuoyian (montelukast sodium tablets/chewable tablets), Zhongnuo Like (ambroxol hydrochloride oral solution) and Zhongnuoping (ambroxol hydrochloride extended-release tablets)
Digestion & metabolism	<ul style="list-style-type: none"> Major products include Debixin (omeprazole enteric capsules/tablets/injections), Linmeixin (glimepiride dispersible tablets), Shuanglexin (metformin hydrochloride tablets/extended-release tablets), Xinweiping (acarbose tablets), and Obeituo (Esomeprazole magnesium enteric-coated capsules)
Others	<ul style="list-style-type: none"> Major products include Oubida (Apgumilast tablets), Gujie (Tofacitib citrate sustained release tablets), Gubang (alendronate sodium tablets/enteric tablets), Xianpai (omeprazole sodium for injection) and Qimaite (tramadol hydrochloride tablets)



Key Products Overview

NBP

Butylphthalide soft capsules and injections

- 1st Class 1 new drug of cardio-cerebrovascular field in China
- Price cut after negotiation improves affordability and accessibility, benefiting more patients
- Significant growth in OTC and E- channels
- New indication - vascular dementia (VaD) under clinical trials

Mingfule

Recombinant human TNK tissue-type plasminogen activator for injection

- For thrombolytic therapy in patients with acute ischemic stroke
- For thrombolysis in patients with acute myocardial infarction within 6h
- Preferred thrombolytic drug recommended by authoritative guidelines such as “*Chinese Expert Consensus on Pre-hospital Thrombolysis*”, “*STEMI Rational Drug Use Guide*”, “*2023 SIGN Clinical Management Guide*”, and “*Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke*”

Ouyuexin

Desvenlafaxine succinate extended-release tablets

- The third-generation antidepressant, the only two-channel drug that does not require dose-titration, easy to use with good safety
- "The second batch of encourage imitation drug catalogue" variety, China's first imitation, exclusive listing
- Approved in 2023, was included in the NRDL the same year, benefiting more depressed patients

Xuanning

Levamlodipine maleate tablets and dispersible tablets

- The first Chinese innovative antihypertensive drug fully approved by the U.S. FDA
- Has served 50 million hypertensive patients in China
- Recommended by authoritative guidelines such as “*China Hypertension Prevention Guide*” and “*Guidelines for Rational Drug Use of Hypertension*”

Anfulike

Amphotericin B cholesteryl sulfate complex for injection

- Exclusive product, obtained marketing approval in March 2021; was included in the NRDL in December 2021
- Have covered approx. 1,600 hospitals
- Form of discoid compound, has a unique drug uptake and release mechanism, significantly decrease nephrotoxicity and increase dosage



Key Products Overview

Jinyouli

PEG-rhG-CSF

- 1st long-acting white blood cell booster drug in China
- Expanding coverage in major municipal hospitals and county-level markets
- Was included in the centralised procurement of the Guangdong Alliance, which consists of 11 provinces, and improving access to the drug would accelerate wider clinical use

Duomeisu

Doxorubicin Hydrochloride liposome injection

- Largest market share in China
- The first player who passed consistency evaluation

Duoenda

Mitoxantrone hydrochloride liposome injection

- Obtained marketing approval in January 2022, exclusive new preparation worldwide authorized by multinational patents, more potent and safer than mitoxantrone
- Was included in the NRDL through negotiation Dec. 2023, benefiting more patients
- Various clinical trails in solid tumors undergoing, blockbuster potential

Duoenyi

Irinotecan hydrochloride liposome injection

- First generic drug in domestic market
- In combination with 5-fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic pancreatic cancer after disease progression following gemcitabine-based therapy
- Recommended by domestic and foreign authoritative guidelines (NCCN/CSCO/CACA)

Jinlitai

Narlumosbart for injection

- The first IgG4 subtype fully human monoclonal antibody against RANKL obtaining marketing approval in the world
- Compared with denosumab, the Product has significant enhancement in uniformity and quality controllability, with favorable efficacy and safety profile
- New indications of tumor bone metastasis and osteoporosis are under development



Bulk Product Business, Functional Food and Others

Bulk vitamin C

- Major products: vitamin C, vitamin C - sodium, vitamin C - calcium and granular vitamin C
- Sales of vitamin C products decreased by 11.8% to RMB486 million due to weakened demand

Bulk antibiotics

- Major products: 7-ACA (intermediate), cefazolin sodium, penicillin potassium, penicillin sodium, azithromycin, and ertapenem sodium
- Sales of antibiotic products remained stable, which decreased slightly by 3.6% to RMB449 million

Functional food and others

- Revenue of the functional food and other business decreased, mainly affected by the decrease in price of caffeine products
- The overall market share of caffeine products has exceeded 60%



Part 03

R & D Capability

R&D Overview



R&D Centre

- 5 R&D centres located in China & the U.S.
- R&D expenses in 2024 1Q: RMB1.17 B



Technology Platform

- 8 national science & technology qualifications
- 2 state key labs
- 8 R&D technology platforms



Project under Development & IPs

- Approx.300 projects under development (approx. 130 innovative drug projects)
- 1856 IPs applications
- 921 IPs authorised




Science Projects & Government Support

- 87 national projects
- RMB890M government grant support
- 8 national prizes


Innovative R&D Platforms

Nano-formulation




- Mitoxantrone liposome
- Albumin-bound docetaxel
- Paclitaxel cationic liposome
- Cisplatin micelle

mRNA vaccine




- Covid-19 mRNA vaccine, RSV mRNA vaccine and various preventive and therapeutic vaccines

siRNA



- PCSK9 siRNA and other chronic disease drugs

ADC



- CLDN18.2 ADC
- Nectin-4 ADC
- EGFR-ADC

BsAb




- JMT601 (CD47/CD20)
- JMT106 (GPC3/IFN)
- JMT108 (**/IL15)

mAb




- JMT101 (EGFR)
- JMT103 (RANKL)
- ALMB0168 (CX43 agonist)
- ALMB0166 (CX43 antagonist)

Small molecule



- Prugliptin (DPP-4)
- Amuxetine
- SYHX1901 (Syk-Jak)
- SYHA1813 (VEGFR/CSF1R)

Long-acting injection



- Octreotide Long-acting injection
- Paliperidone injection
- Leuprorelin microsphere injection

Note: only shows the representative products on each platform

Nano-formulation Platform



Nano-formulation development and manufacturing platform



Novel drug carrier design

- Invented Albumin nanoemulsion
- Developed new cationic materials and new delivery system

Novel drug delivery technology


- Invented ammonium salt gradient method of sulfobutylether- β -cyclodextrin and 5-sulfosalicylate
- Cholesterol PEGylation modification method and post single layer PEGylation

Novel preparation method

- Invented single-phase solution lyophilization technology, O/W type Emulsification technology, crossflow mixing technology, continuous flow reaction technology, etc.
- Invented bottom up nanocrystal preparation technology, enabling continuous production

Novel Industrialized production technology

- Invented continuous flow technology, employing linear amplifier, overcome barriers to industrialized production
- Illustrated that all nano drugs are able to be prepared by permutation and combination of four key processes



Nano-formulation assessment system



Particle characterisation method

- Developed nano-formulation assessment technology for liposome, albumin nanoparticles, emulsion, micelles, etc.

PK determination method

- Established multiple PK determination methods for nano drugs including liposome, albumin nanoparticle, micelles etc.

Mature animal screening models

- Established multiple animal disease model for efficacy assessment
- Established animal models for evaluating ABC phenomenon, CARPA response and HFS, enabling quick screening

Particle characterisation technique guided in vivo PK, PD, TOX evaluation

- Illustrated influence of drug release rate of liposome, mode of administration and animal model on ABC phenomenon
- Detailed study of CARPA and HFS laid the foundations for rational design of nanoparticles

The largest R&D and industrialization base for Nano- Formulation

mRNA Vaccine platform

1 Advantages of antigen design

- Mutation prediction platform
- The combination of bioinformatics and structural biology to obtain effective epitopes
- Superior immunogenicity from site-specific mutation of antigen

2 mRNA vaccine design

- Base modification, UTR screening, codon optimization and structural elements inclusion
- Structural energy optimization to enhance antigen expression

3 Manufacturing capabilities

- Manufacturing capabilities of CSPC
- Top tier LNP R&D platform
- Manufacturing capacity reaches to 1.5 billion doses per year

4 Excellent safety profile

- No observed SAE in clinical trials
- Excipients proven to be low toxicity by launched products
- Base modification mitigates innate immunogenicity
- Formulation ensures long-term stability

5 Streamlined CMC Strategy

- One-step API manufacturing process
- API purification process: up to 99% purity
- Highly scalable LNP manufacturing process
- Short turnaround time: ~2 days

6 Highly expandable platform

- Each individual component can be continuously upgraded
- Expansion from linear mRNA to circRNA; from liver-target delivery to extrahepatic delivery
- From preventive to therapeutic application; from vaccine to CGT



siRNA Platform

1 HTS screening platform

- Rational sequence design based on bioinformatics and experienced scientists
- Comprehensive in vitro and in vivo PK/PD characterization

2 CMC platform

- Build strong oligonucleotides CMC platform based on QbD strategy
- Develop liquid synthesis technology

3 Manufacturing capabilities

- Manufacturing capabilities of CSPC
- Two GMP-compliant production lines have been built

4 Excellent safety profile

- Build off-target risk assessment platform
- Chemical modification to mitigate immunogenicity
- Long-term stability

5 Nucleotides building blocks

- Develop novel building blocks
- Develop Galnac molecule with in-house IP
- Scalable building blocks manufacturing technology

6 Highly expandable platform


- Each individual component can be continuously upgraded
- Integrated manufacturing capabilities for building blocks, API and drug products



1 Payload platform

Multiple payload types for different cancer treatment mechanism of actions

- microtubule inhibitor
- Topoisomerase inhibitors
- Protein degrading agent
- DNA alkylating agent
- DNA repair inhibitors
- Immunoagonists
- Immunosuppressants
- hormone



2 Linker platform

Various linker design for stability, PK and other purpose beneficial for ADCs

- Hydroflex platform ensures hydrophilicity, stability and PK
- TMEC the TME payload released platform overcomes the problem of non-internalize targets
- Novel ESIM self-immolation platform enhances drug release efficiency.
- The HighDAR platform makes it possible to use low potent payloads in ADC

3 Conjugation platform

Including mainstream conjugation technology and proprietary site-specific conjugation technology with IP rights.

- Conventional lysine and cysteine conjugation platforms
- SmartQTag enzyme-mediated conjugation technology
- Glycan-engineered site-specific conjugation technology

4 New molecular entity

Multiple ADC drug molecules provide more clinical treatment options, and overcome the drug resistance of current existing therapies.

ADC Antibody-drug conjugate	ISAC Immune-stimulating antibody conjugate	DAC Degradable-antibody conjugate	dpAC Dual-payload antibody conjugate	CA-ADC Conditional-activated-ADC	Bs-ADC Bispecific-ADC	PDC Peptide-drug conjugate
Cytotoxin	Immune-stimulator	Protein degrader	Synthetic lethal	pH-activated mAb	Dual-epitope	Peptide

Bispecific Antibody Platform

Antibody-interferon fusion protein platform

Structural advantages

- **Synergistic** binding effect when targeting the same cell
- **Smaller** molecular weight (smaller than that of conventional antibodies)

Safer impurities

- The activity of interferon-containing impurities is **far lower** than that of conventional bispecific antibodies.
- No serious safety risk of interferon-containing impurities from the production process


Stronger target selectivity

- Limited binding activity to receptors on TAA – cells, demonstrating a **wider therapeutic window**
- The optimizing of interferon mutation further improves **target selectivity**


More stable product

- More efficient in CMC development
- Significantly reduces the interferon breakage during the production and in vivo, resulting in **high yield** and **low risk**

- ✓ High expandability : quickly forms new molecules
- ✓ Better safety profile : much safer than interferon
- ✓ More effective in tumor killing: much stronger than interferon
- ✓ remodels the tumor immune micro environment: enhances immune cell infiltration and MHC1 presentation
- ✓ Lower production cost : high efficiency, low toxicity, and simple process





CD47-targeting bifunctional fusion protein platform



- ✓ Does not bind to TAA-/CD47+cells, including erythrocytes, platelets, etc.
- ✓ TAA-dependency enhances CD47 competitive binding
- ✓ High expandability: various types of tumor-targeting antibodies could be used as the left-arm
- ✓ Wider safety window
- ✓ Lower molecular weight, better suits solid tumors
- ✓ Simple production process
- ✓ Possession of intellectual property right

Mechanism





Part 04

Pipeline

Candidates under Clinical Trial Stage

(26)

PhI

NBL-012 IL23-P19	NBL-015 CLDN18.2 mAb	NBL-020 TNFR2
NBL-028 CLDN6-CD137	SYS6002 Nectin-4 ADC	SYS6010 EGFR ADC
SYS6011	JMT203 GFRAL	Secukinumab
SYHA1801 BRD4	SYHA1803 Pan-FGFR	SYHA1805 FXRs
SYHA1807 LSD1	SYHA1811 BTK	SYHA1815 FGFR/RET
SYHX1903 CDK9	SYHX2001 PRMT5	SYHX2005 FGFR4
SYHX2009 NTRK/ROS1	SYH2038 SOS1	SYH2043 CDK2/4/6
SYH2045 PRMT5	SYH2051 ATM	SYH2053 PCSK9
SYHA1908		Cisplatin micelle

(15)

PhII (POC)

CLDN18.2 ADC	CM326 TSLP
ALMB0166 Cx43i mAb	ALMB0168 Cx43s mAb
JMT601 CD20/CD47	SYHX1901 JAK/SYK
Simmitinib TKI	SYHA1813 VEGFR/CSF1R
Amuxetine 5-HT/NE	SYHA1402 ARi
NBP Capsule (US PhII)	Paclitaxel cationic liposome
Albumin-bound Sirolimus	Octreotide long- acting injection
Alprostadi liposome	

(18)

PhIII / III pivotal trial

JMT101 EGFR mAb	CM310 IL4R
KN026 Her2 BsAb	TG103 Fc-GLP1
Pertuzumab	Ulsinumab
DP303C HER2 ADC	NBP Capsule (VaD)
Batoclimab	Semaglutide
JMT103 bone metastasis	Pregabalin extended-release tablets
Albumin-bound Paclitaxel II	Pilocarpine hydrochloride eye drops
Clevipidine injectable emulsion	Daunorubicin cytarabine liposome
Albumin-bound Docetaxel	Mitoxantrone hydrochloride liposome (NPC)

(7)

NDA

SYSA1802 PD-1
Omalizumab biosimilar
DBPR108 DDP4
Amphotericin B Liposome
Meloxicam nanocrystal injection
Irinotecan liposome (US)
Amphotericin B Liposome (US)

- Biological Agents
- Chemical Drugs
- New formulations

Pipeline - Biological Agents

Over 40 new biologic drugs under development: 2 filed BLA, 23 under clinical trial stage(9 under pivotal trial stage) and over 10 under pre-clinical stage

TA	Major Candidates	Target	Indication (s)	Pre-clinical	Phase I	Phase II	Ph II / III pivotal trial	NDA	
Oncology	JMT103	RANKL	GCTB, osteoporosis, bone metastasis	Marketed(GCTB)					→
	SYSA1802 (SG001)	PD-1	Tumors	→					★ BLA
	JMT101	EGFR	Multiple solid tumors	→					
	DP303c	HER2 ADC	Breast cancer	→					
	Pertuzumab biosimilar	HER2	Breast cancer	→					
	KN026	HER2 BsAb	Gastric cancer, breast cancer	→					
	SYSA1801*	Claudin 18.2 ADC	Gastric cancer, pancreatic cancer	→					
	ALMB0168	CX43 agonist	Bone cancer, cancer bone metastasis	→					
	JMT601*	CD47/CD20	NHL& multiple hematologic tumors	→					
	SYS6002*	Nectin-4 ADC	Tumors	→					
	NBL-028	CLDN6-CD137	Advanced tumors	→					
	NBL-020*	TNFR2	Advanced solid tumor	→					
	SYS6010*	EGFR ADC	Tumors	→					
	SYS6011	Undisclosed	Solid tumors	→					
	NBL-015*	Claudin 18.2 mAb	Advanced solid tumors	→					
	JMT203	GFRAL	Cancer cachexia	→					

*The product was developed in both China and the U.S.




Pipeline - Biological Agents

TA	Major Candidates	Target	Indication (s)	Pre-clinical	Phase I	Phase II	Ph II / III pivotal trial	NDA
Nervous system	ALMB0166	CX43 antagonist	Spinal cord injury, AIS	→				
	TG103	GLP-1	Obesity, Diabetes	→				
Immune	Omalizumab biosimilar	IgE	Allergic asthma, CIU	→				★ BLA
	Ulsinumab	IL-12/IL-23	Moderate to severe plaque psoriasis	→				
	Batoclimab	FcRn	MG	→				
	CM310	IL-4Rα	Asthma, COPD	→				
	CM326	TSLP	Asthma, COPD	→				
	NBL-012*	IL-23p19	Psoriasis, HS, IBD	→				
	Secukinumab	IL-17A	Psoriasis	→				

*The product was developed in both China and the U.S.

Pipeline - Chemical Drugs

Over 40 small molecule new drugs under development: 1 filed NDA, 23 under clinical trial stage (4 under pivotal trial stage) and about 20 under pre-clinical stage





Pipeline - New formulations

Over 30 new preparations under development: 2 filed NDA, 11 under clinical trial (5 under pivotal trial stage), and over 20 under pre-clinical stage


TA	Major Candidates	Indication(s)	Pre-clinical	Phase I	Phase II	Phase III / Pivotal Clinical Trial	NDA
Oncology	Mitoxantrone hydrochloride liposome injection *	Multiple hematologic neoplasms & solid tumors	[Progress bar]				★ Marketed (PTCL)
	Irinotecan liposome injection*	pancreatic cancer, Breast cancer	[Progress bar]				★ Marketed (pancreatic cancer)
	Daunorubicin cytarabine liposome	Leukemia	[Progress bar]				
	Albumin-bound Paclitaxel II	Multiple solid tumors	[Progress bar]				
	Docetaxel for injection (albumin-bound) *	Gastric cancer, pancreatic cancer	[Progress bar]				
	Paclitaxel cationic liposome	Advanced solid tumors	[Progress bar]				
	Sirolimus for injection (albumin-bound)	Multiple hematologic cancers & solid tumors	[Progress bar]				
	SYHA1908 for injection (class 1 new drug+nano drug)	Solid tumors	[Progress bar]				
	Cisplatin micelle	Multiple solid tumors	[Progress bar]				
Analgesia	Meloxicam nanocrystal injection	Moderate-to-severe pain	[Progress bar]				★ NDA
Anti-infective	Amphotericin B liposome *	Invasive fungal infection	[Progress bar]				★ NDA
Cardio-cerebrovascular	Clevidipine injectable emulsion	Hypertension	[Progress bar]				
	Alprostadil liposome	Vasodilation	[Progress bar]				
Endocrinology	Octreotide long-acting injection	Acromegaly	[Progress bar]				

*The product was developed in both China and the U.S.

Pipeline Products Launch Plan

> Expected 50 New Drugs /Indications to be approved in coming 5 years

- Vaccine
- Biological Agents
- Chemical Drugs
- New formation
- Non-Chinese region





Common Generics Launch Plan

**17 applications have been filed for marketing approvals, expecting to receive approval in 2024-2025;
Over 20 candidates under pharmaceutical research, expecting to receive approval in 2026-2027**

No.	Product	Therapeutic Area	Expected to be launched	Launched or not
1	Dapagliflozin tablets	Digestion & Metabolism	2024	√
2	Rabeprazole sodium enteric-coated tablets (10mg)	Digestion & Metabolism	2024	√
3	Olaparib tablets	Oncology	2024	
4	Palbociclib tablets (125mg)	Oncology	2024	
5	Lenalidomide capsules (5mg, 10mg)	Oncology	2024	
6	Peramivir injection (150mg/15ml)	Anti-infective	2024	√
7	Aprepitant injection	Others	2024	
8	Dexrazoxane for injection	Others	2024	
9	Roxadustat capsules	Others	2024	
10	Peramivir Injection (300mg/60ml)	Anti-infective	2025	
11	Regorafenib tablets	Oncology	2025	
12	Ilaprazole enteric-coated tablets	Digestion & Metabolism	2025	
13	Terezolamide phosphate tablets	Anti-infective	2025	
14	Oseltamivir phosphate for oral suspension	Anti-infective	2025	
15	Mesalazine enteric-coated tablets	Autoimmunity	2025	
16	Vonorazone fumarate tablets	Digestion & Metabolism	2025	
17	Adenosine cobalamin capsules	Others	2025	




IND Approvals Obtained since the beginning of 2024

IND approval for the 1st indication (7+2)	
JMT202 (mAb)	Lower triglyceride (TG) levels in patients with hypertriglyceridaemia
SYS6023 (ADC)	Advanced solid tumors
SYH2039 tablets (MAT2A)	Advanced malignant tumors
Dexmedetomidine hydrochloride nasal spray	Sedation before invasive procedures
Pilocarpine hydrochloride eye drops	Presbyopia
Pregabalin extended-release tablets	Neuropathic pain associated with diabetic peripheral neuropathy
Semaglutide injection	Weight management
JMT106 injection (GPC3/IFN) -US	Advanced solid tumors
SYH2039 tablets (MAT2A enzyme inhibitor) -US	Advanced malignant tumors



IND Approvals Obtained since the beginning of 2024

IND approval for additional indications (9)	
SYSA1801 injection	In combination with CAPOX and SG001 or with irinotecan hydrochloride liposome injection for first-line and second-line treatment of Claudin18.2-positive gastric cancer
JMT101 injection	In combination with docetaxel (albumin-bound) for treatment of second-line and above EGFR lung squamous cell carcinoma
Simmitnib hydrochloride tablets	In combination with irinotecan liposome for the treatment of second-line advanced esophageal cancer
Sirolimus for injection (albumin-bound)	In combination with endocrine therapy for the treatment of second-line and above HR-positive HER2-negative advanced breast cancer after failure of standard therapy
Sirolimus for injection (albumin-bound)	In combination with gometinib for the treatment of locally advanced/recurrent or distant metastasis MET-overexpression non-small cell lung cancer
SYH2043 tablets	In combination with fulvestrant for the treatment of advanced breast cancer
Cisplatin micelle injection	In combination with paclitaxel for the treatment of advanced solid tumors
Octreotide long-acting injection	Gastroenteropancreatic neuroendocrine tumors
Irinotecan liposome injection	In combination with oxaliplatin and tegafur for adjuvant treatment of pancreatic cancer



Part 05
BD&ESG

BD Strategic Layout and Path of Advancement

Focusing on strategic domains, deepening BD strategies, and establishing an international BD ecosystem

BD Product Positioning: Aligning closely with clinical needs, emphasizing clinical benefits, grasping international cutting-edge technology and product trends, strengthening areas of group advantage, focusing on key clinical stage products in the mid to late phases.

BD Technology Platforms: Actively exploring collaboration and development of early-stage products with AI pharmaceuticals, nucleic acid drug antigen screening platforms, gene therapy technologies, novel vaccine development platforms, and intratumoral injection technology platform.

Internationalization of BD: Pursuing a dual strategy of both licensing in and out, expanding international projects with leading multinational pharmaceutical companies and Belt and Road initiatives, reinforcing strategic relationships with fund institutions having overseas resources, and advancing the connection and collaboration of global projects.

BD Ecosystem Construction : BD Ecosystem Construction: Leveraging the advantages of group clinical development, product registration, and commercialization resources, adopting a Pharma+Biotech win-win model, engaging in extensive and in-depth collaboration with Biotech companies or research institutions that possess innovative advantages, including practical and feasible merger and acquisition models, to continue supporting the group's external innovation.

BD Work Completion Status for 2023

■ License-out:

- Granted Corbus Pharmaceuticals the development and commercialization rights for SYS6002 (Nectin-4ADC, Phase 1) in the United States, European Union countries, the United Kingdom, Canada, Australia, Iceland, Liechtenstein, Norway, and Switzerland.

■ License-in:

- Obtained Pfizer's exclusive authorization to locally market the oral antiviral COVID-19 treatment medication, Namatavir Tablets/Litoconavir Tablets, in China



BD Key Therapeutic Area Strategy for 2024

Reinforce Leading Position in Established Areas


- Comprehensive Management of Stroke Disease, with a Focus on the Strategic Positioning and Collaboration of Innovative Drug Projects in Vascular Recanalization, Neuroprotection, and Anti-Inflammation that Synergize with the Company's Existing Resources
- Attention to Late-stage Clinical or Newly Approved Drugs in the Alzheimer's Disease (AD) Field, as well as Emerging Novel Targeted Therapeutics.

Neurology Field



- Strengthen differentiation in hematologic malignancies, lung cancer, and breast cancer, focusing on targeted therapies, new immunotherapies, and combination treatments.
- Explore innovative drugs in areas such as digestive tract tumors, gynecological tumors, and urological tumors.
- .

Oncology Field



- Focus on challenging areas like refractory hypertension, hyperlipidemia, and heart failure. Pay attention to long-acting, oral diabetes/weight reduction innovative products.
- Address thyroid diseases and innovative treatments related to gout.

Cardiovascular & Endocrinology Field



- Emphasize areas like idiopathic pulmonary fibrosis (IPF), COPD/asthma, and cough, exploring innovative targets, drug-device combinations, and drug delivery systems.
- Focus on high-end antibiotics effective against clinically resistant bacteria.
- Address conditions such as atopic dermatitis, systemic lupus erythematosus, and inflammatory bowel disease (IBD).

Respiratory, Autoimmune & Anti-Infective Field



Explore Novel Therapeutic Areas and Technology Platforms

- Address primary and secondary kidney diseases like IgA nephropathy and diabetic nephropathy.
- Focus on complications of kidney diseases like renal anemia, hyperphosphatemic kidney disease, hypertension, and kidney-related itching.

Nephrology Field



- Concentrate on well-established companies with mature late-stage ophthalmology pipelines.
- Focus on products for treating retinal diseases like AMD using new targets, long-acting formulations, nanomedicines, and gene therapies, with a special focus on geographic atrophy indications.

Ophthalmology Field



- Focus on therapeutic nuclear medicine, breaking through new targets, new indications, and new isotopes while avoiding homogenization.
- Focus on larger market opportunities in solid tumor such as prostate cancer, lung cancer, breast cancer, gastrointestinal tumors under new nuclides and new target combination

Nuclear Medicine Field



- Expand into major population-based psychiatric disorders like depression and schizophrenia, focusing on the layout and collaboration of novel targeted drugs with improved efficacy, safety, and compliance.
- Emphasize fast-acting nasal spray formulations.

Psychiatry Field



- Chronic Pain: Focus on innovative drug projects that provide better pain relief, higher safety, and non-addictive properties.
- Acute Pain: Concentrate on innovative projects that extend postoperative pain relief duration while maintaining higher safety.

Pain Management Field




- Focus on unmet clinical needs in orthopedics, from completely innovative products to products that improve patient accessibility, and tap opportunities in orthopedics
- Focus on spine surgery-related drugs, osteoporosis iterations

Orthopedics Field



Aim to Become an ESG Leader in Pharmaceutical Industry



- Awarded “China’s Top Healthiest Workplace” by Mercer, “AAA Enterprise with Harmonious Labour Relations in Hebei Province” and “National Advanced Enterprise in Employment”

- Achieved “Five Zeros and One Low”**
- The major shareholder of the Group granted 220M conditional shares to over 300 employees in 2022

- Improving board diversity continuously
- Structural reduction of carbon emissions - the ratio of innovative drugs /formulations increasing and the ratio of APIs decreasing
- Invested RMB763m in smart manufacturing, equipment upgrade and modification
- Plan to invest more than RMB100m per year to support the upgrade of environment protection center
- Ouyi, NBP, CSPC Innovation, Factory in Taizhou (our subsidiaries) are recognized as “Green Factories” by the MIIT

- Adhere to the procurement principle of “fair, impartial, green and transparent”
- Online bidding and procurement; supplier integrity commitment; *Blacklist Management System for Dishonesty*

- Employee assistance: In 2023, a total of 81 employees and their families were helped
- CSPC Education Assistant Fund-helped 2024 college students in 2023
- Cancer and critical illness patients assisting program- assisted 42 patients in 2023
- Medical care program for poor children- helped 42 children with hemopathy in 2023
- Patient assisting program: the number of aid recipients reached 59300 in 2023.



Environmental Protection Plan 2025

- ✓ Reduce greenhouse gas emissions per unit of revenue by 50.66%
- ✓ Reduce the emission of non-hazardous waste (general solid waste) per unit of revenue by 70.7%
- ✓ Reduce the discharge of hazardous waste per unit of revenue by 26%
- ✓ Reduce the comprehensive energy consumption by 56.57%
- ✓ Reduce the water consumption per unit of revenue by 35.52%



**Five Zeros and One Low- zero cases of death, serious injuries, multiple injuries, occupational disease and poisoning incident as well as low incident rate of minor injuries

*The emission reduction target is based on the emission in 2017



WeChat of CSPC IR Team:



Thanks!